BioRegenx, Inc. (BRGX)
OTCMKTS · Delayed Price · Currency is USD
0.0120
+0.0020 (20.00%)
Jan 20, 2026, 9:30 AM EST

BioRegenx Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
0.050.060.1300.880.59
Cash & Short-Term Investments
0.050.060.1300.880.59
Cash Growth
-33.01%-53.43%18450.59%-99.92%48.76%-
Receivables
0.060.010.1-0-
Inventory
0.110.110.22-0.650.85
Prepaid Expenses
0.010.010.06-0.240.16
Other Current Assets
0.050.120.14-0.110.26
Total Current Assets
0.270.310.6501.891.87
Property, Plant & Equipment
0.170.20.01-0.02-
Long-Term Investments
---0.02--
Other Intangible Assets
0.73-0.050.04--
Other Long-Term Assets
--0.15-0.010.01
Total Assets
1.170.510.870.061.921.88
Accounts Payable
0.850.650.460.020.611.89
Accrued Expenses
0.910.880.64-10.72
Short-Term Debt
1.031.030.96-1.320.5
Current Portion of Long-Term Debt
1.040.880.380.05--
Current Unearned Revenue
0.10.20.35-0.07-
Total Current Liabilities
3.933.632.790.062.993.11
Long-Term Debt
0.180.250.150.22.190.77
Total Liabilities
4.813.892.940.265.183.89
Common Stock
0.961.230.770.2700.01
Additional Paid-In Capital
31.4930.979.682.442.70.41
Retained Earnings
-36.1-35.57-12.52-2.92-5.96-0.56
Comprehensive Income & Other
-0-0---1.86
Total Common Equity
-3.65-3.38-2.07-0.21-3.26-2
Shareholders' Equity
-3.65-3.38-2.07-0.2-3.26-2
Total Liabilities & Equity
1.170.510.870.061.921.88
Total Debt
2.252.161.490.243.511.27
Net Cash (Debt)
-2.21-2.11-1.36-0.24-2.62-0.68
Net Cash Per Share
-0.00-0.00-0.00-0.00-0.07-0.02
Filing Date Shares Outstanding
961.99956.99956.6338.8836.1734.91
Total Common Shares Outstanding
961.99956.99956.6338.5836.1734.91
Working Capital
-3.66-3.33-2.13-0.06-1.11-1.24
Book Value Per Share
-0.00-0.00-0.00-0.01-0.09-0.06
Tangible Book Value
-4.37-3.38-2.12-0.25-3.26-2
Tangible Book Value Per Share
-0.00-0.00-0.00-0.01-0.09-0.06
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.